S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

About this episode

Dr. Jacob Sands discusses the evolving treatment landscape for small cell lung cancer, focusing on new therapies and challenges in patient outcomes.

In today’s episode, we spoke with Jacob Sands, MD. Dr Sands is the associate chief of the Lowe Center for Thoracic Oncology, Oncology Medical Director of the International Patient Center, and physician at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. In our exclusive interview, Dr Sands discussed the rapidly evolving treatment landscape for small cell lung cancer (SCLC), emphasizing both the progress made with immunotherapy and the ongoing challenges associated with this aggressive disease. He noted that outcomes now vary widely, with some patients experiencing long-term durable disease control following checkpoint inhibitor therapy, while others continue to have limited benefit from currently available treatments. A major focus of the discussion centered on tarlatamab-dlle (Imdelltra), the DLL3-targeting bispecific T-cell engager approved for relapsed SCLC . Sands described tarlatamab as a “new paradigm” therapy, highlighting results from the phase 3 DeLLphi-304 trial (NCT05740566) showing superiority in progression-free survival, overall survival, symptom improvement, and toxicity outcomes vs chemotherapy in…

People in this episode

Guests: Jacob Sands, MD, Jacob Sands

Topics covered

• small cell lung cancer
• immunotherapy
• treatment landscape
• DLL3-targeting therapies
• checkpoint inhibitor therapy

Keywords

• small cell lung cancer
• immunotherapy
• tarlatamab
• DLL3
• checkpoint inhibitors
• treatment outcomes

Mentioned in this episode

Organizations: Dana-Farber Cancer Institute, Harvard Medical School

Products: tarlatamab-dlle (Imdelltra), rovalpituzumab tesirine (Rova-T)

More episodes of OncLive® On Air

• S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD · June 10, 2026 · 10 min
• S17 Ep31: ASCO 2026 Plenary: RASolute 302 · June 8, 2026 · 11 min
• S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy · June 5, 2026 · 32 min
• S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD · June 1, 2026 · 30 min
• S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD · May 28, 2026 · 30 min
• S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD · May 27, 2026 · 16 min